The role of PTP1B activity inhibition has been identified in hepatocyte proliferation and liver regeneration, which could, hence, be instrumental in treating NAFLD patients (Chen et al., 2015). This evidence concerns the gene PTPN1 and metabolic dysfunction-associated steatotic liver disease.